O
11.80
0.59 (5.26%)
Market Trend
Short Term | Medium Term | ||
Industry | Biotechnology (US) | Bearish | Bearish |
Biotechnology (Global) | Bearish | Bearish | |
Stock | Oruka Therapeutics, Inc. | Bullish | - |
AIStockmoo Score
0.1
Analyst Consensus | 1.5 |
Insider Activity | NA |
Price Volatility | -2.0 |
Technical Moving Averages | 2.5 |
Technical Oscillators | -1.5 |
Average | 0.13 |
Oruka Therapeutics Inc is developing novel biologics designed to set a new standard for the treatment of chronic skin diseases. It is to offer patients suffering from chronic skin diseases like plaque psoriasis. |
|
Sector | Healthcare |
Industry | Biotechnology |
% Held by Insiders | 3.25% |
% Held by Institutions | 86.54% |
52 Weeks Range | ||
Median | 40.00 (238.98%) | |
Total | 1 Buy |
Firm | Date | Target Price | Call | Price @ Call |
---|---|---|---|---|
Wedbush | 15 May 2025 | 40.00 (238.98%) | Buy | 9.46 |
No data within this time range.
Date | Type | Details |
---|---|---|
01 Jul 2025 | Announcement | Oruka Therapeutics Announces Promotion of Laura Sandler to Chief Operating Officer |
21 May 2025 | Announcement | Oruka Therapeutics to Present at the Jefferies Global Healthcare Conference |
20 May 2025 | Announcement | Oruka Therapeutics Announces First Participants Dosed in Phase 1 Trial of ORKA-002, its Novel Half-life Extended Anti-IL-17A/F Antibody |
14 May 2025 | Announcement | Oruka Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update |
29 Apr 2025 | Announcement | Oruka Therapeutics to Present at Bank of America Securities 2025 Health Care Conference |
TTM Dividend Yield | 13.67% |
1Y Average Dividend Yield | 8.32% |
Expected Next Dividend Payment | Aug 2025 |
Ex Date | Announcement Date | Payment Date | Details |
---|---|---|---|
29 Aug 2024 | - | 28 Aug 2024 | 1.613 Cash |
Annual Dividend Yield
Year | Annual Dividend ($) | Frequency/Year | Yield % |
---|---|---|---|
2024 | 1.61 | 1 | 8.32 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
Realized Profit | - |
Unrealized Profit | - |
Dividend Received 2025 | - |
Total Profit | - |
Avg. Return | - |
Quantity (Buy) | - |
Avg. Price (Buy) | - |
Quantity (Sold) | - |
Avg. Price (Sold) | - |